MedTrace Logo

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

NCT00994214 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2019-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.

Conditions

Interventions

DRUG

BIM 23A760

Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States
  • Belgium
  • Brazil
  • Czechia
  • France
  • Latvia
  • Lithuania
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994214 on ClinicalTrials.gov